Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters








Language
Year range
1.
Mem. Inst. Oswaldo Cruz ; 104(7): 1023-1030, Nov. 2009. tab, ilus
Article in English | LILACS | ID: lil-534170

ABSTRACT

We investigated whether sequestered Trypanosoma cruzi antigens found in heart interstitial dendritic cells (IDCs) contribute to the residual myocarditis found in mice following treatment with benznidazole, a specific chemotherapeutic drug. IDCs are antigen-presenting cells that are MHC-II-receptor dependent. Swiss mice were divided into two experimental groups: the 1st group was infected with the Colombian strain of T. cruzi, which is resistant to treatment with benznidazole, and the 2nd group was infected with clone 21SF-C 3, which has a medium susceptibility to the drug. Treatment of the Colombian strain group started on the 120th day post-infection and for the 21SF-C3 strain group treatment was started on the 90th day. In both groups, treatment lasted for 90 days. The animals were sacrificed either 150 or 200 days post-treatment. The myocardium was analysed by immunohistochemistry using anti-MAC3, 33D1, CD11b and CD11c monoclonal antibodies for IDCs or anti-T. cruzi purified antibodies. Parasite antigens were expressed on the IDC membranes in both treated and untreated mice. Myocarditis subsided following treatment, evidenced by both histological and morphometrical evaluation. A reduction in the number of IDCs carrying T. cruzi antigens in the treated group indicates that the elimination of parasites influences antigen presentation with concomitant decreases in inflammation. There is a correlation between the presence of T. cruzi antigens in these cells and the chronic focal, residual myocarditis seen in treated mice.


Subject(s)
Animals , Mice , Antigens, Protozoan/analysis , Chagas Cardiomyopathy/immunology , Dendritic Cells/immunology , Myocarditis/immunology , Myocardium/cytology , Trypanosoma cruzi/immunology , Antibodies, Monoclonal/blood , Antigens, Protozoan/drug effects , Chagas Cardiomyopathy/drug therapy , Chagas Cardiomyopathy/pathology , Disease Models, Animal , Drug Resistance , Dendritic Cells/pathology , Myocarditis/drug therapy , Myocarditis/pathology , Myocardium/immunology , Nitroimidazoles/therapeutic use , Time Factors , Trypanocidal Agents/therapeutic use , Trypanosoma cruzi/classification
2.
Braz. j. med. biol. res ; 39(12): 1525-1536, Dec. 2006. ilus
Article in English | LILACS | ID: lil-439686

ABSTRACT

Malaria is undoubtedly the world's most devastating parasitic disease, affecting 300 to 500 million people every year. Some cases of Plasmodium falciparum infection progress to the deadly forms of the disease responsible for 1 to 3 million deaths annually. P. falciparum-infected erythrocytes adhere to host receptors in the deep microvasculature of several organs. The cytoadhesion of infected erythrocytes to placental syncytiotrophoblast receptors leads to pregnancy-associated malaria (PAM). This specific maternal-fetal syndrome causes maternal anemia, low birth weight and the death of 62,000 to 363,000 infants per year in sub-Saharan Africa, and thus has a poor outcome for both mother and fetus. However, PAM and non-PAM parasites have been shown to differ antigenically and genetically. After multiple pregnancies, women from different geographical areas develop adhesion-blocking antibodies that protect against placental parasitemia and clinical symptoms of PAM. The recent description of a new parasite ligand encoded by the var2CSA gene as the only gene up-regulated in PAM parasites renders the development of an anti-PAM vaccine more feasible. The search for a vaccine to prevent P. falciparum sequestration in the placenta by eliciting adhesion-blocking antibodies and a cellular immune response, and the development of new methods for evaluating such antibodies should be key priorities in mother-child health programs in areas of endemic malaria. This review summarizes the main molecular, immunological and physiopathological aspects of PAM, including findings related to new targets in the P. falciparum var gene family. Finally, we focus on a new methodology for mimicking cytoadhesion under blood flow conditions in human placental tissue.


Subject(s)
Humans , Animals , Female , Pregnancy , Erythrocytes/parasitology , Malaria, Falciparum/immunology , Placenta/parasitology , Plasmodium falciparum/immunology , Pregnancy Complications, Parasitic/immunology , Protozoan Proteins/immunology , Antibodies, Protozoan/blood , Antibodies, Protozoan/immunology , Antigens, Protozoan/blood , Antigens, Protozoan/drug effects , Antigens, Protozoan/genetics , Antigens, Protozoan/immunology , Cell Adhesion/physiology , Erythrocytes/immunology , Malaria Vaccines , Malaria, Falciparum/blood , Plasmodium falciparum/genetics , Plasmodium falciparum/physiology , Pregnancy Complications, Parasitic/blood , Protozoan Proteins/blood , Protozoan Proteins/drug effects
3.
Acta physiol. pharmacol. ther. latinoam ; 48(3): 115-23, 1998. tab, graf
Article in English | LILACS | ID: lil-216879

ABSTRACT

Here we demonstrate that T. cruzi antigen molecule SAPA (shed acute phase antigen) with neuraminidase-trans sialidase activity triggers down-regulation of T lymphocyte proliferation by interacting with T lymphocyte muscarinic acetylcholine receptors (mAChR). SAPA attachment to mAChR from Lyt 2.2+ T cells resulted in synthesis of cyclic GMP (cGMP) and secretion of PGE2, an immunoregulator effector substance. These T suppressor cell signals were blunted by atropine and by indomethacin. Cell sorter analysis showed that the interaction of SAPA with purified T cells, affected the ratio of L3T4+/Lyt 2.2+ T cells increasing the percentage of Lyt 2.2+ T cells, effect that was inhibited by the mAChR antagonist, atropine. The interaction between SAPA and mAChR from Lyt 2.2+ T cells may result, therefore, in the down-regulation of the host immune response as consequence of T suppressor/cytotoxic cells activation and PGE2 release as they were observed. These results support the theory of an immunosuppressive state that contribute to the chronic course of Chagas'disease.


Subject(s)
Animals , Mice , Antigens, Protozoan/drug effects , Atropine/pharmacology , Cyclooxygenase Inhibitors/pharmacology , Dinoprostone/metabolism , Down-Regulation/drug effects , Indomethacin/pharmacology , Muscarinic Antagonists/pharmacology , Receptors, Muscarinic/immunology , T-Lymphocytes/drug effects , Trypanosoma cruzi/immunology , Cell Division , Chagas Disease/immunology , Chronic Disease , Concanavalin A , Cyclic GMP/immunology , Dinoprostone/immunology , Flow Cytometry , Mice, Inbred BALB C , T-Lymphocytes/cytology , T-Lymphocytes/immunology
SELECTION OF CITATIONS
SEARCH DETAIL